If you've ever been around cancer care, you know the side effects are not some side quest. They are the thing that can send someone to the emergency department at 2 a.m., derail treatment, or turn a normal Tuesday into a very bad Tuesday. Chemotherapy works because it hits fast-dividing cells, but...
Three little metabolites in urine - glycine, alanine, and citrate - are what make this ovarian cancer study different from the usual biomarker parade, and honestly, that is a pretty wild sentence to get from a paper about prognosis.[1]
Biliary tract cancers are a rough group of diseases. They include tumors in the bile ducts and gallbladder, and they often get diagnosed late, when surgery is no longer an option. That is a big reason researchers keep chasing better systemic treatments. Even with recent progress, these cancers...
Prostate cancer is a sly little operator. Give it one blocked escape route and it starts checking the walls for vents, windows, and suspiciously loose ceiling tiles. That is why this new study on B7-H3 feels so interesting: the researchers may have found a target that stays visible across a wide...
Molecular imaging has serious dating-app energy: one tracer is obsessed with who is burning sugar right now, the other wants to know who is actually planning a future. In this new phase II trial in triple-negative breast cancer, FDG-PET turned out to be the better matchmaker for early treatment...
When I was a kid, I had one of those toy doctor kits with a plastic stethoscope that made me feel like I could handle anything from a scraped knee to, presumably, the collapse of modern civilization. Adult medicine is less adorable. Chronic lymphocytic leukemia, or CLL, is a good example: we have...
Drug delivery in cancer can feel like a public transit system run during a snowstorm - the bus has to keep moving, but one wrong stop and you either miss the clot or crash into a bleed. That, in one rude sentence, is the problem this new meta-analysis tackles: when a person with cancer gets a...
That is the punchline from this new colorectal cancer imaging paper: the probe stayed mostly quiet until it hit the exact biochemical weirdness of tumor tissue, then switched on hard enough to help separate cancer from normal tissue during surgery. Rewind a bit, because this is where cancer biology...
The odds here were brutal from the first shuffle: relapsed AML after a donor stem cell transplant is the kind of clinical poker game where the house usually wins, the chips are on fire, and somebody in the back is yelling "what if we engineered the security team?" That, more or less, is where...
Mantle cell lymphoma, or MCL, is one of those blood cancers that behaves like a wily evolutionary opportunist. It is a B-cell lymphoma, which means it starts in immune cells that are supposed to help protect you, then promptly defects and starts freelancing for chaos. In many patients, the first...
Occult cancer is the villain here. It does not kick the door down. It slips in quietly, messes with the wiring, and sometimes the first screaming alarm is a seizure.
Diffuse large B-cell lymphoma, or DLBCL, is the most common aggressive lymphoma. Many patients do well with R-CHOP, which has been the dependable workhorse for years. But DEL is the version that shows up wearing sunglasses indoors. These tumors overexpress MYC, which pushes cells to grow and...
Excavating a buried city is mostly dust, patience, and the occasional brushstroke that reveals a hidden doorway. This paper feels a bit like that: researchers kept scraping away at the mess of biological background noise and uncovered a mechanism that lets a tumor-imaging probe keep glowing after...
Cancer cells make a ridiculous amount of stuff. Proteins, signaling molecules, membrane parts, survival tricks - the whole factory is running overtime, with somebody definitely ignoring OSHA. That creates a traffic jam inside a cell compartment called the endoplasmic reticulum, where proteins get...
Advanced ovarian cancer has a nasty habit of looking under control, then trying to sneak back in later like a villain who definitely fell off the cliff but somehow got a sequel. That is why maintenance therapy exists. After surgery and platinum-based chemotherapy, doctors try to keep the cancer...
p53 is one of your cells' main quality-control bosses. When DNA gets damaged, p53 can slam the brakes on cell division, call in repair crews, or order the cell to self-destruct if things look beyond repair. That is why people call it the "guardian of the genome." Very dramatic, very deserved. When...
A CD30-targeted immune therapy can make the whole trip to a Hodgkin lymphoma cell, swipe its ticket at the membrane, and still get stuck in a sugar traffic jam right outside the front door. That, in gloriously weird cancer-biology fashion, is the setup for this new study on classical Hodgkin...
Most cancer scans tell you what the tumor looks like - size, shape, spread, whether it seems to be causing trouble like a tiny criminal with a real estate portfolio. Useful, yes. But looks are not the whole story. Tumors also have habits. They burn fuel differently, hoard nutrients, and rewire...
Precision cancer therapy has a funny contradiction at its core: sometimes the best way to control a drug is not to deliver the finished drug at all, but to smuggle in the parts and let the cell assemble the contraption only when you flip the lights on.
The study, led by Sun and colleagues, looked at 546 blood samples from 160 patients with high-risk stage II/III HER2-negative breast cancer getting neoadjuvant treatment, meaning therapy before surgery. Some received chemotherapy alone, while others got chemotherapy plus immunotherapy. The team ran...